市場調查報告書

單純皰疹病毒(HSV)感染疾病:市場考察,流行病學,市場預測 (2027年)

Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 602068
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
單純皰疹病毒(HSV)感染疾病:市場考察,流行病學,市場預測 (2027年) Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家單純皰疹病毒(HSV)感染疾病的患病數,2016年推定為2億2855萬2,199人,同年的單純皰疹病毒(HSV)感染疾病市場估算為40億美元。

本報告提供單純皰疹病毒(HSV)感染疾病市場相關調查,提供疾病概要,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的市場趨勢,患病數及市場規模的預測(今後10年份),總括性彙整市場成長要素及障礙分析,正在開發/已上市的治療藥的簡介,潛在成長性,目前未滿足需求等資訊。

目錄

第1章 重要洞察

第2章 單純皰疹病毒(HSV)感染疾病市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病的背景和概要:單純皰疹病毒(HSV)感染疾病

  • 簡介
  • 分期
  • 臨床症狀
  • 危險因素
  • 病因
  • 徵兆
  • 發病機制
  • 診斷

第4章 流行病學和患者人口

第5章 主要觀察

  • 疾病定義
  • 患者人口與預測參數
  • 主要7個國家HSV感染疾病的患病數
  • 主要7個國家HSV感染疾病的患病數:各類型

第6章 單純皰疹病毒(HSV)感染疾病的流行病學:各國

  • 美國
    • HSV感染疾病的患病數
    • HSV感染疾病的患病數:各類型
    • HSV感染疾病的罹患數
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 治療指南

  • 美國疾病管理預防中心(CDC)
  • WHO
  • 歐洲

第8章 未滿足需求

第9章 已上市的治療藥

  • Abreva: GSK/Avanir Pharmaceuticals
    • 藥物的說明
    • 法規的里程碑
    • 優點與缺點
    • 產品的簡介
  • Viroptic Opthalmic Solution (trifluridine) 1%: Pfizer Inc.
  • Famvir: Novartis
  • Valtrex: GlaxoSmithKline
  • Denavir: Mylan Pharmaceuticals
  • Foscavir: Clinigen Group Plc
  • Sitavig/Sitavir: BioAlliance Pharma
  • Zovirax: GlaxoSmithKline
  • Lipsovir: Medivir

第10章 新的治療方法

第11章 多元的競爭

第12章 開發中治療藥(第二階段/III期實驗)

  • SQX770:Squarex
    • 藥物的說明
    • 產品的簡介
    • 臨床開發
    • 臨床試驗資訊
  • BTL TML HSV: Beech Tree Labs
  • GEN 003: Genocea Biosciences
  • Pritelivir: AiCuris
  • VCL-HB01: Vical
  • M5210B:Maruho

第13章 單純皰疹病毒(HSV)感染疾病:市場分析

  • 主要的觀察
  • 主要7個國家的市場規模
  • 主要7個國家的市場規模:不同臨床症狀
  • 主要7個國家的市場規模:治療類別

第14章 單純皰疹病毒(HSV)感染疾病的市場規模:各國

  • 美國
    • 市場規模
    • 市場規模:不同臨床症狀
    • 市場規模:治療類別
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第15章 成長要素

第16章 市場障礙

第17章 附錄

  • 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0297

DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Herpes Simplex market report provides current treatment practices, emerging drugs, Herpes Simplex market share of the individual therapies, current and forecasted Herpes Simplex market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Herpes Simplex treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Herpes Simplex Disease Understanding and Treatment Algorithm

The DelveInsight Herpes Simplex market report gives a thorough understanding of the Herpes Simplex by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Herpes Simplex.

Treatment

It covers the details of conventional and current medical therapies available in the Herpes Simplex market for the treatment of the condition. It also provides Herpes Simplex treatment algorithms and guidelines in the United States, Europe, and Japan.

Herpes Simplex Epidemiology

The Herpes Simplex epidemiology division provide insights about historical and current Herpes Simplex patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Herpes Simplex epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Herpes Simplex Epidemiology

The epidemiology segment also provides the Herpes Simplex epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Herpes Simplex Drug Chapters

Drug chapter segment of the Herpes Simplex report encloses the detailed analysis of Herpes Simplex marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Herpes Simplex clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Herpes Simplex treatment.

Herpes Simplex Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Herpes Simplex treatment.

Herpes Simplex Market Outlook

The Herpes Simplex market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Herpes Simplex market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Herpes Simplex market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Herpes Simplex market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Herpes Simplex market in 7MM.

The United States Market Outlook

This section provides the total Herpes Simplex market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Herpes Simplex market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Herpes Simplex market size and market size by therapies in Japan is also mentioned.

Herpes Simplex Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Herpes Simplex market or expected to get launched in the market during the study period 2017-2030. The analysis covers Herpes Simplex market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Herpes Simplex Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Herpes Simplex key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Herpes Simplex emerging therapies.

Reimbursement Scenario in Herpes Simplex

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Herpes Simplex domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Herpes Simplex market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Herpes Simplex Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Herpes Simplex, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Herpes Simplex epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Herpes Simplex are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Herpes Simplex market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Herpes Simplex market

Report Highlights

  • In the coming years, Herpes Simplex market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Simplex R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Herpes Simplex. Launch of emerging therapies will significantly impact the Herpes Simplex market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Herpes Simplex
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Herpes Simplex Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Herpes Simplex Pipeline Analysis
  • Herpes Simplex Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Herpes Simplex Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Herpes Simplex Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Herpes Simplex Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Herpes Simplex market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Herpes Simplex total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Herpes Simplex market size during the forecast period (2017-2030)?
  • At what CAGR, the Herpes Simplex market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Herpes Simplex market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Herpes Simplex market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Herpes Simplex?
  • What is the historical Herpes Simplex patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Herpes Simplex in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Herpes Simplex?
  • Out of all 7MM countries, which country would have the highest prevalent population of Herpes Simplex during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Herpes Simplex treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Herpes Simplex in the USA, Europe, and Japan?
  • What are the Herpes Simplex marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Herpes Simplex?
  • How many therapies are developed by each company for Herpes Simplex treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Herpes Simplex treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Herpes Simplex therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Herpes Simplex and their status?
  • What are the key designations that have been granted for the emerging therapies for Herpes Simplex?
  • What are the global historical and forecasted market of Herpes Simplex?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Herpes Simplex market
  • To understand the future market competition in the Herpes Simplex market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Herpes Simplex in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Herpes Simplex market
  • To understand the future market competition in the Herpes Simplex market

Table of Contents

1. Key Insights

2. Executive Summary of Herpes Simplex

3. Competitive Intelligence Analysis for Herpes Simplex

4. Herpes Simplex: Market Overview at a Glance

  • 4.1. Herpes Simplex Total Market Share (%) Distribution in 2017
  • 4.2. Herpes Simplex Total Market Share (%) Distribution in 2030

5. Herpes Simplex: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Herpes Simplex Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Herpes Simplex Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Herpes Simplex Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Herpes Simplex Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Herpes Simplex Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Herpes Simplex Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Herpes Simplex Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Herpes Simplex Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Herpes Simplex Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Herpes Simplex Treatment and Management
  • 8.2. Herpes Simplex Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Herpes Simplex Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Herpes Simplex: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Herpes Simplex Market Size in 7MM
  • 13.3. Herpes Simplex Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Herpes Simplex Total Market Size in the United States
    • 15.1.2. Herpes Simplex Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Herpes Simplex Total Market Size in Germany
    • 15.3.2. Herpes Simplex Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Herpes Simplex Total Market Size in France
    • 15.4.2. Herpes Simplex Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Herpes Simplex Total Market Size in Italy
    • 15.5.2. Herpes Simplex Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Herpes Simplex Total Market Size in Spain
    • 15.6.2. Herpes Simplex Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Herpes Simplex Total Market Size in the United Kingdom
    • 15.7.2. Herpes Simplex Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Herpes Simplex Total Market Size in Japan
    • 15.8.3. Herpes Simplex Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Herpes Simplex

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Herpes Simplex Epidemiology (2017-2030)
  • Table 2 : 7MM Herpes Simplex Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Herpes Simplex Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Herpes Simplex Epidemiology in Germany (2017-2030)
  • Table 6 : Herpes Simplex Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Herpes Simplex Epidemiology in France (2017-2030)
  • Table 8 : Herpes Simplex Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Herpes Simplex Epidemiology in Italy (2017-2030)
  • Table 10 : Herpes Simplex Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Herpes Simplex Epidemiology in Spain (2017-2030)
  • Table 12 : Herpes Simplex Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Herpes Simplex Epidemiology in the UK (2017-2030)
  • Table 14 : Herpes Simplex Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Herpes Simplex Epidemiology in Japan (2017-2030)
  • Table 16 : Herpes Simplex Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Herpes Simplex Epidemiology (2017-2030)
  • Figure 2 : 7MM Herpes Simplex Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Herpes Simplex Epidemiology in the United States (2017-2030)
  • Figure 4 : Herpes Simplex Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Herpes Simplex Epidemiology in Germany (2017-2030)
  • Figure 6 : Herpes Simplex Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Herpes Simplex Epidemiology in France (2017-2030)
  • Figure 8 : Herpes Simplex Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Herpes Simplex Epidemiology in Italy (2017-2030)
  • Figure 10 : Herpes Simplex Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Herpes Simplex Epidemiology in Spain (2017-2030)
  • Figure 12 : Herpes Simplex Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Herpes Simplex Epidemiology in the UK (2017-2030)
  • Figure 14 : Herpes Simplex Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Herpes Simplex Epidemiology in Japan (2017-2030)
  • Figure 16 : Herpes Simplex Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)